Acute Intracranial Hemorrhage clinical trials at UC Irvine

• Trial of Andexanet in ICH Patients Receiving an Oral FXa Inhibitor

  open to eligible people ages 18-89

  Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet versus usual standard of care in patients with intracranial hemorrhage anticoagulated with a direct oral anticoagulant

  Orange, California and other locations

Last updated: July 6, 2021